Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: A meta-analysis

Urology

Volumn 82, Issue 2, 2013, Pages 327-334

  Tsai, Huei Ting ^a   Penson, David F ^b,c   Makambi, Kepher H ^a   Lynch, John H ^d   Van Den Eeden, Stephen K ^e   Potosky, Arnold L ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

^d GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^e DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ARTICLE; ATTRIBUTABLE RISK; CANCER MORTALITY; CANCER SURVIVAL; COMPARATIVE STUDY; CONTINUOUS ANDROGEN DEPRIVATION THERAPY; DEMOGRAPHY; DISEASE COURSE; DISEASE SPECIFIC SURVIVAL; HISTOLOGY; HUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW;

ANDROGEN ANTAGONISTS; CONFIDENCE INTERVALS; DISEASE PROGRESSION; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; ODDS RATIO; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 84880884233     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2013.01.078     Document Type: Article

References (26)

1. M. Ismail, M. Ferroni, and L.G. Gomella Androgen suppression strategies for prostate cancer: is there an ideal approach? Curr Urol Rep 12 2011 188 196
2. E. Youssef, S. Tekyi-Mensah, and K. Hart Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer Am J Clin Oncol 26 2003 e119 e123
3. S.M. Gilbert, Y.F. Kuo, and V.B. Shahinian Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States Urol Oncol 29 2009 647 653
4. N. Bruchovsky, P.S. Rennie, and A.J. Coldman Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma Cancer Res 50 1990 2275 2282
5. N. Sato, M.E. Gleave, and N. Bruchovsky Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumor model J Steroid Biochem Mol Biol 58 1996 139 146
6. N.D. Shore, and E.D. Crawford Intermittent androgen deprivation therapy: redefining the standard of care? Rev Urol 12 2010 1 11
7. A. Heidenreich, G. Aus, and M. Bolla EAU guidelines on prostate cancer Eur Urol 53 2008 68 80
8. U.K. National Institute for Health and Clinical Excellence, in Prostate Cancer: Diagnosis and Treatment. Cardiff, UK: National Collaborating Centre for Cancer, 2008. Available at: http://www.nice.org.uk/nicemedia/pdf/ CG58FullGuideline.pdf. Accessed October 8, 2012.
9. F.E. Calais da Silva, A.V. Bono, and P. Whelan Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group Eur Urol 55 2009 1269 1277
10. J.M. Crook, C.J. O'Callaghan, and G. Duncan Intermittent androgen suppression for rising PSA level after radiotherapy N Engl J Med 367 2012 895 903
11. J. de Leval, P. Boca, and E. Yousef Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial Clin Prostate Cancer 1 2002 163 171
12. J.F. Langenhuijsen, D. Badhauser, and B. Schaaf Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer Urol Oncol 2011 [Epub ahead of print]
13. N. Mottet, J. Van Damme, and S. Loulidi Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial BJU Int 2012 [Epub ahead of print]
14. A.J. Salonen, K. Taari, and M. Ala-Opas The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer J Urol 187 2012 2074 2081
15. M. Hussain, C.M. Tangen, and C.S. Higano Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): results of S9346 (INT-0162), an international phase III trail. 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition) J Clin Oncol 30 suppl 18 2012 (June 20 Supplement-Abstract 4)
16. J. Irani, O. Celhay, and J. Hubert Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study Eur Urol 54 2008 382 391
17. J.P. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Stat Med 21 2002 1539 1558
18. F.E. Calais da Silva, F. Goncalves, and A. Santos Evaluation of quality of life, side effects and duration of therapy in a phase 3 study of intermittent monotherapy versus continuous combined androgen deprivation Eur Urol 7 2008 205 (abstract 540)
19. P.C.M.S. Verhagen, L.D. Wissenburg, and M.F. Wildhagen Quality of life effects of intermittent and continuous hormonal therapy by cyproterone acetate (CPA) for metastatic prostate cancer Eur Urol 7 2008 206
20. K. Miller, U. Steiner, and A. Lingnau Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition) J Clin Oncol 25 suppl 18 2007 (June 20-Supplement-Abstract 5015)
21. U.W. Tunn, G. Canepa, and H. Hillger Intermittent androgen deprivation in patients with PSA-Relapse after radical prostatectomy - final results of a European randomized prospective phase-III clinical trial AUO study AP 06/95, EC 507 J Urol 177 2007 201
22. S.M. Alibhai, M. Duong-Hua, and R. Sutradar Impact of androgen deprivation therapy (ADT) on bone, cardiovascular, and endocrine outcomes: a propensity-matched analysis of 20,000 patients. 2008 ASCO Annual Meeting Proceedings (post-meeting edition) J Clin Oncol 26 suppl 15 2008 (May 20-Supplement-Abstract 5012)
23. N.L. Keating, A.J. O'Malley, and S.J. Freedland Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer J Natl Cancer Inst 102 2010 39 46
24. G.N. Levine, A.V. D'Amico, and P. Berger Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology Circulation 121 2010 833 840
25. A. Nanda, M.H. Chen, and M.H. Braccioforte Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction JAMA 302 2009 866 873
26. V.B. Shahinian, Y.F. Kuo, and J.L. Freeman Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 2005 154 164